Pfizer and Lifera Forge Alliance to Boost Saudi Pharmaceutical Manufacturing

Editorial Team

Last updated 27-10-2025

3 min

Pfizer Saudi Arabia and Lifera signed an MoU advancing local drug production in the Kingdom.

This agreement aligns with Saudi Vision 2030's goals of medicine security and economic diversification.

The collaboration includes knowledge-sharing and aims to boost local innovation and talent development.

Lifera focuses on leveraging global expertise to enhance Saudi healthcare and biotech sectors.

The MoU represents a significant step in strengthening regional health and biotech partnerships.

Pfizer Saudi Arabia and Lifera have inked a memorandum of understanding that could mark a turning point for local drug production in the Kingdom. The agreement, announced during the first day of the Global Health Exhibition in Riyadh, aims to explore how both sides can join forces to boost pharmaceutical manufacturing and, in turn, strengthen national medicine security — a key goal under Vision 2030.

It’s not just about pills and factories. This deal sits neatly within a broader Saudi–U.S. partnership that’s spreading its wings beyond oil — into healthcare, artificial intelligence, and even space exploration. For a country intent on reducing its dependency on imports, this collaboration could be spot on. Focusing on knowledge-sharing and home‑grown innovation, both parties are pushing the envelope on what it means to “think local” in a highly regulated, global industry.

Nick Lagunowich, who leads Pfizer’s emerging markets, said the agreement builds on the company’s ongoing commitment to Saudi industrial progress. He noted that investing in local talent and transferring advanced technologies aren’t just buzzwords — they’re tangible steps towards higher-quality care and a diversified economy.

Meanwhile, Dr Mohamed Fawzy, Pfizer Saudi’s country manager, highlighted that the MoU represents a new chapter in public–private teamwork. He explained that the partnership is designed to make the local ecosystem stronger through new technologies and world-class expertise reaching Saudi soil.

If you ask me, that’s easier said than done — localisation can be a bit of a faff, especially when scaling up cutting‑edge production. But the payoff? A more resilient healthcare system and new opportunities for skilled Saudis. Those are the sort of wins that Arageek readers often tell me make all the hard work worthwhile.

The agreement also ties into ongoing efforts to nurture research, development, and investment in local manufacturing. Lifera, a Public Investment Fund company established in 2023, has quickly become a focal point for these goals. Its business units cover everything from insulin and monoclonal antibodies to genetic testing and precision medicine — a bold portfolio for such a new player.

Lifera’s approach is quite straightforward: bring global expertise into Saudi Arabia while training up the next generation of homegrown scientists. It’s a plan that, if executed well… could redefine the healthcare supply chain for the region.

All told, this MoU signals ambition — on both sides. And while I reckon the road ahead will take patience and a fair few adjustments along the way, one can’t help feeling a touch chuffed to bits seeing how regional collaboration is slowly reshaping the future of health and biotech in Saudi Arabia.

(And yes, I definately think this story is one worth keeping an eye on.)

🚀 Got exciting news to share?

If you're a startup founder, VC, or PR agency with big updates—funding rounds, product launches 📢, or company milestones 🎉 — AraGeek English wants to hear from you!